Clinical Development > Overview
............................................................................................................................................................................................................................................................................................................

 Overview

Rexahn is developing drugs for large therapeutic markets with significant unmet needs, such as cancer, CNS disorders, and sexual dysfunction. Our clinical stage drugs include Archexin^TM, Serdaxin^TM, and Zoraxel^TM. Archexin^TM is a first-in-class, potent inhibitor of the Akt-1 protein kinase in cancer cells. Archexin^TM is in Phase II trials for treatment of renal cell carcinoma (RCC) and pancreatic cancer, and has US FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of ovary, stomach and pancreas). Multiple indications for other solid tumors may be pursued. Serdaxin^TM is being developed to treat depression and mood disorders, and has proven and well-established safety in humans. SerdaxinTM Phase IIa trials for treatment of depression have been successfully completed. Zoraxel^TM is a CNS-based or centrally acting sexual dysfunction drug, and may be the first ED drug to affect all three phases of sexual activity (sexual arousal, erection and release). Zoraxel^TM Phase IIa trials for treatment of erectile dysfunction are in progress.